Does CYP2C19 genotype affect clinical outcome?

被引：7

作者：

ten Berg, Jurrien M. ^{[1
]}

Deneer, Vera H. ^{[2
]}

机构：

[1] St Antonius Hosp, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands

[2] St Antonius Hosp, Dept Clin Pharmacol, NL-3435 CM Nieuwegein, Netherlands

来源：

NATURE REVIEWS CARDIOLOGY | 2012年 / 9卷 / 04期

关键词：

CLOPIDOGREL; METAANALYSIS; POLYMORPHISMS;

D O I：

10.1038/nrcardio.2012.29

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.

引用

页码：192 / 194

页数：3

共 10 条

[1] CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis [J].

Holmes, Michael V. ;

Perel, Pablo ;

Shah, Tina ;

Hingorani, Aroon D. ;

Casas, Juan P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (24) :2704-2714

[2] Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite [J].

Kazui, Miho ;

Nishiya, Yumi ;

Ishizuka, Tomoko ;

Hagihara, Katsunobu ;

Farid, Nagy A. ;

Okazaki, Osamu ;

Ikeda, Toshihiko ;

Kurihara, Atsushi .

DRUG METABOLISM AND DISPOSITION, 2010, 38 (01) :92-99

[3] Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease [J].

Mega, Jessica L. ;

Hochholzer, Willibald ;

Frelinger, Andrew L., III ;

Kluk, Michael J. ;

Angiolillo, Dominick J. ;

Kereiakes, Dean J. ;

Isserman, Steven ;

Rogers, William J. ;

Ruff, Christian T. ;

Contant, Charles ;

Pencina, Michael J. ;

Scirica, Benjamin M. ;

Longtine, Janina A. ;

Michelson, Alan D. ;

Sabatine, Marc S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (20) :2221-2228

[4] Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis [J].

Mega, Jessica L. ;

Simon, Tabassome ;

Collet, Jean-Philippe ;

Anderson, Jeffrey L. ;

Antman, Elliott M. ;

Bliden, Kevin ;

Cannon, Christopher P. ;

Danchin, Nicolas ;

Giusti, Betti ;

Gurbel, Paul ;

Horne, Benjamin D. ;

Hulot, Jean-Sebastian ;

Kastrati, Adnan ;

Montalescot, Gilles ;

Neumann, Franz-Josef ;

Shen, Lei ;

Sibbing, Dirk ;

Steg, P. Gabriel ;

Trenk, Dietmar ;

Wiviott, Stephen D. ;

Sabatine, Marc S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1821-1830

[5] Cytochrome P-450 Polymorphisms and Response to Clopidogrel. [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William ;

Braunwald, Eugene ;

Sabatine, Marc S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (04) :354-362

[6] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment [J].

Pare, Guillaume ;

Mehta, Shamir R. ;

Yusuf, Salim ;

Anand, Sonia S. ;

Connolly, Stuart J. ;

Hirsh, Jack ;

Simonsen, Katy ;

Bhatt, Deepak L. ;

Fox, Keith A. A. ;

Eikelboom, John W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1704-1714

[7] Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy [J].

Sibbing, D. ;

Gebhard, D. ;

Koch, W. ;

Braun, S. ;

Stegherr, J. ;

Morath, T. ;

Von Beckerath, N. ;

Mehilli, J. ;

Schoemig, A. ;

Schuster, T. ;

Kastrati, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (08) :1685-1693

[8] Clopidogrel non responsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis [J].

Snoep, Jaapjan D. ;

Hovens, Marcel M. C. ;

Eikenboom, Jeroen C. J. ;

van der Bom, Johanna G. ;

Jukema, J. Wouter ;

Huisman, Menno V. .

AMERICAN HEART JOURNAL, 2007, 154 (02) :221-231

[9]

US Department of Health and Human Services, FDA DRUG SAF COMM RE

[10] Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial [J].

Wallentin, Lars ;

James, Stefan ;

Storey, Robert F. ;

Armstrong, Martin ;

Barratt, Bryan J. ;

Horrow, Jay ;

Husted, Steen ;

Katus, Hugo ;

Steg, P. Gabriel ;

Shah, Svati H. ;

Becker, Richard C. .

LANCET, 2010, 376 (9749) :1320-1328

← 1 →